Sep 11, 2026 · 13 min · 9 segments
Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from…
Preeti MalaniHostThis week, JAMA also published commentary from this year's Lasker Award winners.
Minow and Yanagisawa won the 2026 Albert Lasker Basic Medical Research Award for their work in identifying orexin, a brain peptide that maintains wakefulness.
The linkage of orexin deficiency to narcolepsy changes how we understand sleep regulation.
This opens the door to new sleep disorder therapies, including orexin antagonists for insomnia and orexin agonists for narcolepsy.
They also discuss links between orexin loss and influenza, as well as potential applications for orexin agonists spanning many psychiatric and neurological conditions.
Hattori Kitazawa and Igawa share the 2026 Lasker-DeBakey Clinical Medical Research Award for the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia.
Beyond improving hemophilia treatment, their work showed that antibodies can be engineered to replace a missing biologic function, not just block a specific target.
Fox emphasizes that patient-centered philanthropy can accelerate research and biomarker discovery.
He highlights that philanthropy alone cannot meet the scale of the problem and that broader public and private investment is still necessary.
This week, JAMA also published commentary from this year's Lasker Award winners.
Minow and Yanagisawa won the 2026 Albert Lasker Basic Medical Research Award for their work in identifying orexin, a brain peptide that maintains wakefulness.
The linkage of orexin deficiency to narcolepsy changes how we understand sleep regulation.
This opens the door to new sleep disorder therapies, including orexin antagonists for insomnia and orexin agonists for narcolepsy.
They also discuss links between orexin loss and influenza, as well as potential applications for orexin agonists spanning many psychiatric and neurological conditions.
Hattori Kitazawa and Igawa share the 2026 Lasker-DeBakey Clinical Medical Research Award for the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia.
Beyond improving hemophilia treatment, their work showed that antibodies can be engineered to replace a missing biologic function, not just block a specific target.
Fox emphasizes that patient-centered philanthropy can accelerate research and biomarker discovery.
He highlights that philanthropy alone cannot meet the scale of the problem and that broader public and private investment is still necessary.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
